Scientists try to 'Wake Up' immune system to fight tough colon cancer
NCT ID NCT03388190
Summary
This study tested if adding an immunotherapy drug (nivolumab) to standard chemotherapy could better control a hard-to-treat type of advanced colorectal cancer. It involved 80 patients who had not received prior treatment for their metastatic cancer. The main goal was to see if the new combination could delay cancer growth longer than chemotherapy alone.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Akershus University Hospital
Oslo, 1478, Norway
-
Haukeland University Hospital
Bergen, 5021, Norway
-
Hospital of Southern Norway, Department of Oncology
Kristiansand, 4604, Norway
-
Oslo University Hospital
Oslo, 0424, Norway
-
St Olav's Hospital - Trondheim University Hospital
Trondheim, 7006, Norway
Conditions
Explore the condition pages connected to this study.